Apimeds Pharmaceuticals US, Inc. 8-K/A

What Happened
Apimeds Pharmaceuticals US, Inc. (APUS) announced that a March 20, 2026 written stockholder consent from Inscobee Inc. and Apimeds, Inc. (Apimeds Korea) — which purported to remove directors Elona Kogan, Jakap Koo, Carol O’Donnell and Dr. Bennett Weintraub and to remove CEO Dr. Vin Menon and CFO Erick Frim — is null and void. The company says the consent violated the Stockholder Support and Lock-Up Agreement entered in connection with the Merger Agreement (closed December 1, 2025), including an irrevocable proxy, an anti-frustration covenant, and a waiver of consent rights. The company specifically notes 6,416,365 shares used in the consent were subject to an irrevocable proxy that the company (as proxy holder) did not authorize.

Key Details

• Stockholder Consent date: March 20, 2026; Merger closed: December 1, 2025.
• Parties involved: Inscobee Inc. and Apimeds, Inc. (Apimeds Korea) vs. APUS and MindWave Innovations (via merger/subsidiary).
• 6,416,365 shares were used in the challenged consent and are claimed to be subject to an irrevocable proxy in the Support Agreement.
• APUS says the Support Agreement provisions (irrevocable proxy, anti-frustration covenant, waiver of consent rights) make the consent void ab initio.
• APUS will proceed with actions described in its Schedule 14C Information Statement (filed Feb 27, 2026; first mailed Mar 5, 2026).

Why It Matters
For investors, this filing clarifies that the company considers the attempted removals of its board members and top officers invalid, preserving current management and director control while APUS moves forward with the transaction-related actions described in its Schedule 14C. The dispute centers on voting control and contractual rights over millions of shares tied to the recent merger, which could affect corporate governance and the implementation of the merger-related plan. The company’s position, if upheld, reduces near-term governance uncertainty; however, investors should watch for any legal challenges or follow-up disclosures.